AU2007281381A1 - Phytoestrogenic formulations and uses thereof - Google Patents
Phytoestrogenic formulations and uses thereof Download PDFInfo
- Publication number
- AU2007281381A1 AU2007281381A1 AU2007281381A AU2007281381A AU2007281381A1 AU 2007281381 A1 AU2007281381 A1 AU 2007281381A1 AU 2007281381 A AU2007281381 A AU 2007281381A AU 2007281381 A AU2007281381 A AU 2007281381A AU 2007281381 A1 AU2007281381 A1 AU 2007281381A1
- Authority
- AU
- Australia
- Prior art keywords
- estrogen
- formulation
- erp
- era
- binding
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/30—Oestrogens
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Endocrinology (AREA)
- Rheumatology (AREA)
- Hospice & Palliative Care (AREA)
- Dermatology (AREA)
- Psychiatry (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Diabetes (AREA)
- Reproductive Health (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Plant Substances (AREA)
Applications Claiming Priority (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US81984906P | 2006-08-02 | 2006-08-02 | |
US60/819,849 | 2006-08-02 | ||
US88992007P | 2007-02-14 | 2007-02-14 | |
US60/889,920 | 2007-02-14 | ||
US94319007P | 2007-06-11 | 2007-06-11 | |
US60/943,190 | 2007-06-11 | ||
PCT/US2007/073505 WO2008016768A1 (fr) | 2006-08-02 | 2007-07-13 | Formulations phyto-œstrogéniques pour soulager ou prévenir des maladies neurodégénératives |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU2011236080A Division AU2011236080A1 (en) | 2006-08-02 | 2011-10-17 | Phytoestrogenic formulations and uses thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
AU2007281381A1 true AU2007281381A1 (en) | 2008-02-07 |
Family
ID=38672818
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU2007281381A Abandoned AU2007281381A1 (en) | 2006-08-02 | 2007-07-13 | Phytoestrogenic formulations and uses thereof |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP2046325A1 (fr) |
JP (1) | JP2009545605A (fr) |
AU (1) | AU2007281381A1 (fr) |
CA (1) | CA2659905A1 (fr) |
WO (1) | WO2008016768A1 (fr) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2676066C (fr) | 2007-01-22 | 2016-06-28 | Gtx, Inc. | Agents se liant aux recepteurs nucleaires |
US9623021B2 (en) | 2007-01-22 | 2017-04-18 | Gtx, Inc. | Nuclear receptor binding agents |
US9604931B2 (en) | 2007-01-22 | 2017-03-28 | Gtx, Inc. | Nuclear receptor binding agents |
US9333192B2 (en) | 2010-02-15 | 2016-05-10 | Sinoveda Canada, Inc | Phytoestrogen product of red clover and pharmaceutical uses thereof |
WO2013050930A1 (fr) * | 2011-10-02 | 2013-04-11 | Sinoveda Canada, Inc, | Développement d'un produit de phytoestrogène de trèfle des prés pour la prévention ou le traitement de l'ostéoporose |
EP3490551A2 (fr) * | 2016-07-26 | 2019-06-05 | Ausio Pharmaceuticals, LLC | Méthodes de diagnostic et de traitement de la maladie d'alzheimer par s-équol |
BR112019004540A2 (pt) * | 2016-09-12 | 2019-05-28 | Hoffman Steven | método para tratar demência em um paciente, composição farmacêutica, método para tratar demência em um paciente, método para reduzir a probabilidade de desenvolver demência em um paciente, composição para uso no tratamento de demência em um paciente, composição e composição para uso na redução da probabilidade de desenvolver demência em um paciente submetido a uma terapia longa de um fármaco não-esteroide anti-inflamatório ou aspirina |
WO2022071670A1 (fr) * | 2020-09-29 | 2022-04-07 | 주식회사 뉴로바이오넷 | Dérivé de 3-phényl-2h-chromène et composition pharmaceutique le contenant pour la prévention ou le traitement de la maladie d'alzheimer |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2160371A1 (fr) * | 1993-04-16 | 1994-10-27 | The Trustees Of Tufts College | Methode pour le traitement des symptomes menopausiques et premenstruels |
NZ527735A (en) * | 1997-05-01 | 2005-10-28 | Novogen Inc | Treatment or prevention of menopausal symptoms and osteoporosis |
US6436923B1 (en) * | 1999-03-17 | 2002-08-20 | Signal Pharmaceuticals, Inc. | Compounds and methods for modulation of estrogen receptors |
AUPQ008399A0 (en) * | 1999-04-28 | 1999-05-27 | Novogen Research Pty Ltd | Cariovascular applications |
US20040072765A1 (en) * | 1999-04-28 | 2004-04-15 | Novogen Research Pty Ltd. | Cardiovascular and bone treatment using isoflavones |
EP1345914A1 (fr) * | 2000-12-22 | 2003-09-24 | AstraZeneca AB | Composes therapeutiques |
BR0313182A (pt) * | 2002-07-24 | 2007-07-24 | Childrens Hosp Medical Center | composições e produtos contendo equol enantiomérico |
ES2559777T3 (es) * | 2004-03-17 | 2016-02-15 | Nestec S.A. | Composiciones y métodos para reducir o prevenir la obesidad |
-
2007
- 2007-07-13 JP JP2009522917A patent/JP2009545605A/ja active Pending
- 2007-07-13 EP EP07812924A patent/EP2046325A1/fr not_active Withdrawn
- 2007-07-13 AU AU2007281381A patent/AU2007281381A1/en not_active Abandoned
- 2007-07-13 CA CA002659905A patent/CA2659905A1/fr not_active Abandoned
- 2007-07-13 WO PCT/US2007/073505 patent/WO2008016768A1/fr active Application Filing
Also Published As
Publication number | Publication date |
---|---|
WO2008016768A1 (fr) | 2008-02-07 |
WO2008016768A8 (fr) | 2008-06-12 |
CA2659905A1 (fr) | 2008-02-07 |
JP2009545605A (ja) | 2009-12-24 |
EP2046325A1 (fr) | 2009-04-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US8552057B2 (en) | Phytoestrogenic formulations for alleviation or prevention of neurodegenerative diseases | |
AU2007281381A1 (en) | Phytoestrogenic formulations and uses thereof | |
US6524616B1 (en) | Compositions and methods for treating or preventing neurodegeneration and cognitive decline and dysfunction associated with alzheimer's disease, aging, other dementia related disorders and estrogen deficiency related conditions | |
TWI258369B (en) | Pharmaceutical compositions of a selective estrogen receptor modulator in combination with sex steroid precursors | |
Norbury et al. | The neuroprotective effects of estrogen on the aging brain | |
US20040192598A1 (en) | Composition and method of alleviating adverse side effects and/or enhancing efficacy of agents that inhibit aromatase | |
US20220323464A1 (en) | Composition, formulations and methods of making and using botanicals and natural compounds for the promotion of healthy brain aging | |
KR20200108505A (ko) | 선택적 에스트로겐 수용체 조절자와 복합된 성 스테로이드 전구체에 의한 알츠하이머병, 인지 상실, 기억 상실 및 치매의 치료 | |
Pratchayasakul et al. | Effects of estrogen in preventing neuronal insulin resistance in hippocampus of obese rats are different between genders | |
JP2020520966A (ja) | Trpv1を標的にするミルセン及びカンナビノイド含有組成物 | |
Guo et al. | Research progress of melatonin (MT) in improving ovarian function: a review of the current status | |
Yu et al. | Cycloastragenol prevents age-related bone loss: evidence in d-galactose-treated and aged rats | |
US8680140B2 (en) | Phytoestrogenic formulations for alleviation or prevention of menopausal symptoms | |
Miville-Godbout et al. | Plasmalogen precursor mitigates striatal dopamine loss in MPTP mice | |
AU2011236080A1 (en) | Phytoestrogenic formulations and uses thereof | |
JP5569949B2 (ja) | うつ病を治療するための、選択的セロトニン再取り込み阻害剤およびグルココルチコイド受容体拮抗薬を含む薬物組み合わせ | |
US20120269793A1 (en) | Phytoestrogenic formulations for alleviation or prevention of hair loss | |
US20110091435A1 (en) | Phytoestrogenic formulations for alleviation or prevention of hair loss | |
Zhao et al. | ESTROGEN THERAPY FOR PREVENTING ALZHEIMER'S DISEASE: THERAPEUTIC STRATEGIES TO ADDRESS HORMONE THERAPY CHALLENGE FOR THE BRAIN | |
KR20220054565A (ko) | 부틸히드록시아니솔, 부틸히드록시톨루엔 또는 이들의 혼합물을 포함하는 남성 생식기 질환의 예방 또는 치료용 약학적 조성물 | |
AU2011236053B2 (en) | Drug combination comprising a selective serotonin reuptake inhibitor and a glucocorticoid receptor antagonist for the treatment of depression | |
Ho | The involvement of estrogen receptor (ER) and G protein-coupled estrogen receptor (GPR30) in rapid cellular signaling of phytoestrogens in osteoblasts | |
Bernardino | Evaluation of the antioxidant action of the G protein-coupled estrogen receptor | |
Landry et al. | EFFECT OF ESTRADIOL AND SELECTIVE ESTROGEN RECEPTOR MODULATORS ON MEMBRANE DOPAMINE AND VESICULAR MONOAMINE TRANSPORTERS IN | |
Singh et al. | 99 TESTOSTERONE MODULATES TRANSFORMING GROWTH FACTOR [beta] SIGNALING PATHWAY GENES IN MESENCHYMAL PLURIPOTENT C3H 10T1/2 STEM CELLS: IMPLICATIONS IN REGULATION OF BODY COMPOSITION. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PC1 | Assignment before grant (sect. 113) |
Owner name: UNIVERSITY OF SOUTHERN CALIFORNIA Free format text: FORMER APPLICANT(S): ZHAO, LIQIN; BRINTON, ROBERTA |
|
MK5 | Application lapsed section 142(2)(e) - patent request and compl. specification not accepted |